H Company Launches Next-Generation Autonomous AI Agents for Enterprise and Consumer Markets
PARIS--(BUSINESS WIRE)-- H Company, a leading European AI Research and Product company backed by $220 million from tier-one investors, today announced the public launch of its autonomous AI agent platform featuring three specialized agents built to carry out complex digital tasks with human-in-the-loop.
'We are witnessing the transition from conversational AI to execution intelligence,' said Charles Kantor, Co-founder and Chairman of H Company.
Share
The launch includes:
Runner H™, an orchestration platform for multi-step task completion,
Surfer H™, a web-native agent for browser-based automation,
Tester H™, an enterprise solution for automated software testing.
The company simultaneously open-sourced Holo-1, its proprietary visual-language model, in partnership with Hugging Face, Nvidia (NIM soon available) and AWS (Amazon).
Transforming AI from Assistants to Executors
H Company's current product selection supports its aim of making trusted, action-oriented AI agents available to organizations of all sizes. H Company's agents, which are built on proprietary multimodal models, bridge the gap by combining planning and vision capabilities to deliver measurable business outcomes.
'We are witnessing the transition from conversational AI to execution intelligence,' said Charles Kantor, Co-founder and Chairman of H Company. 'Entering the era, where agents don't just assist—they complete entire workflows autonomously, delivering the productivity gains enterprises have been seeking from AI investments."
Runner H
Runner H serves as H Company's flagship orchestration platform, delivering "intelligence in motion" by enabling users to accomplish complex, multi-step objectives through a single natural language prompt and is now available to the public.
Runner H dynamically coordinates specialized sub-agents and integrates with existing enterprise applications (including MCPs and agnostic interactions proprietary and additional agents), supporting seamless workflows across web browsers, document systems, and business applications while maintaining cost-effectiveness at scale.
Surfer H
Surfer H operates as a web-native automation agent, navigating browser environments with human-like precision while delivering cost-effective automation solutions. Unlike API-dependent solutions, Surfer H interacts directly with web interfaces, enabling deployment across any website without custom integrations or compatibility requirements, creating a powerful, general-purpose, cost-effective web automation system.
Tester H
Tester H addresses enterprise software testing challenges by converting natural language test scenarios into executable automated testing protocols. The platform supports both web and mobile applications, enabling teams to scale quality assurance processes without expanding technical testing resources.
Proven Performance Metrics
Benchmark testing demonstrates H Company's agents deliver superior cost-performance ratios and optimal value propositions compared to existing market solutions:
Surfer H achieved 92.2% task completion accuracy on the WebVoyager benchmark at just $0.13 per task, establishing the strongest tradeoff between accuracy and cost.
Performance exceeds that of major technology providers while reducing operational costs by up to 10 times, setting the Pareto frontier for performance-per-dollar.
Holo-1 visual-language model achieves 76.2% UI localization accuracy with affordable inference costs, leading performance among models under 7B parameters (the highest small-size model overall).
Open Source Strategy Accelerates Market Adoption
H Company's release of Holo-1 under Apache 2.0 licensing enables developers and enterprises to build production-ready custom automation solutions using visual AI capabilities. The model delivers commercial-grade accuracy for UI understanding and interaction.
The open-source initiative includes the WebClick dataset, featuring 1,639 real-world UI interaction scenarios designed to advance industry-wide development of visual AI applications.
Market Availability and Enterprise Adoption
Runner H is immediately available for public access, in waves, while Tester H targets enterprise customers requiring automated software testing capabilities. The platform's browser-based agent, Surfer H, ensures compatibility with existing enterprise privacy requirements, addressing key concerns for large-scale organizational deployment.
About H Company
H Company is a next-generation AI research and product company pioneering the future of autonomous, agentic AI. Founded to build intelligence that acts—not just reacts—H Company is creating the foundational infrastructure for autonomous AI systems that drive real-world outcomes across industries. With $220 million in funding, H Company is backed by leading global investors including Accel, Eric Schmidt and Yuri Milner.
To learn more, visit hcompany.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Europe's biggest VCs are going to war over adopting China's 996 ‘always on' culture: ‘Don't listen to a jumped-up finance bro in a hoodie'
A war is brewing in Europe's startup community over three numbers that would have mass implications for tech workers, and perhaps beyond: 996. Stoked by an ongoing debate about Europe's competitiveness with other territories, leaders of some of the region's biggest VCs have waded into a battle startups should be working in order to compete with U.S. and Chinese tech firms. Harry Stebbings, founder of the 20VC fund, ignited the latest debate last weekend when he said Silicon Valley had 'turned up the intensity,' and European founders needed to take notice. '7 days a week is the required velocity to win right now. There is no room for slip up,' Stebbings said on LinkedIn. 'You aren't competing against random company in Germany etc but the best in the world.' His fellow venture capitalist, Index Ventures partner Martin Mignot, followed up in a lengthy post raising the idea of tech startups needing to work long, intense hours now more than ever. The fast-moving world of AI left no time for complacency, Mignot argued, in addition to the emergence of global competition and the need to maximize productivity among workers in a scarce talent pool. In his post, Mignot cited a 2018 Financial Times editorial by Michael Moritz, the Welsh billionaire chairperson of Sequoia Capital, who suggested Silicon Valley entrepreneurs adopt the then-little-known 996 model. It's where employees work from nine to nine, six days a week, adding up to a 72-hour work week, or double the average weekly working hours in the EU. Mignot credited Moritz with introducing the 996 model to a Western audience. A representative for Index Partners didn't respond to a request for comment. Stebbings' and Mignot's remarks caught the attention of both Amelia Miller, co-founder of Ivee, and Suranga Chandratillake, a general partner at Balderton Capital. 'Burnout [is] one of the top 3 reasons early-stage ventures fail. It is literally a bad reason to invest,' said Ivee's Miller on LinkedIn. Balderton's Chandratillake shared Miller's sentiment, and leveled his criticism at the messengers calling for a 996 culture: 'All the versions of this post I've read are from VCs who've never built a technology company themselves. I remember such 'advice' well when I was a founder. If you're a CEO, don't listen to a jumped-up finance bro in a hoodie who has never done your job telling you how to do it!' Chandratillake tells Fortune he felt compelled to wade into a public argument on the train home from work after reading what he thought were new versions of a 'dangerous' conversation on expected working hours. The former startup founder has seen the negative effects of that 'always on' mentality from some founders he has watched knowingly or unknowingly adopt the 996 model. Those founders tend to 'fail in a slightly depressing, sinking out of significance kind of way,' he said. 'You get addicted to this thing of, 'I'm just gonna make these incremental improvements in my company.' And you're growing a little bit every day, you're building a little bit every day, but you completely miss some big strategic shift that's going on around you, and as a result, you just don't make the right pivot.' The 'always on' narrative is compelling because it's an easy explanation for complex problems, Chandratillake believes. 'I always say Californians are great at telling stories, right? There's a reason why Hollywood is in LA,' said Chandratillake. 'If a thing takes 10 or 20 years to build, there's just no way you can sprint for that long without stopping.' Through Balderton, Chandratillake has been an investor in cutting-edge wellness programs for the founders of its portfolio companies, using methods practised by astronauts and athletes to ensure recovery and prevent burnout. While he advocates for more awareness of physical and mental health among founders, Chandratillake doesn't go as far as to support the idea of work-life balance. He admits he would frequently pull all-nighters at critical moments, like around funding rounds and quarterly deadlines, while building the startup Blinkx, which he eventually took public. 'You have to be smart about having moments to balance yourself, not because you're trying to create this wonderful work-life balance existence, but because you know that in a couple of weeks time, there's going to be a crunch.' The argument surrounding work culture in Europe isn't new, as opposing voices seek to support or dismiss the idea that a cross-Atlantic divergence in productivity growth is a result of differing work ethic. The sparse number of European tech companies populating the Fortune 500, or the list of the world's most valuable companies, has been used as a prime example of the fallout of this perceived shortfall. Last year, Nicolai Tangen, the CEO of Norway's $1.8 trillion wealth fund, Norges Bank Investment Management, claimed Americans work harder than Europeans owing to a higher 'general level of ambition.' Speaking on Stebbings' 20VC podcast last year, Monzo co-founder and serial entrepreneur, Tom Blomfield, took a more nuanced approach, singling out the U.K., where he felt the concept of the 'American Dream' was 'antithetical to British culture.' Chandratillake said he doesn't subscribe to the idea that Europe is being left behind, and envisions at least three European companies—Spotify, ASML, and Arm—he thinks can hit a $1 trillion+ valuation in the future. 'We might be behind from a timing point of view, but I don't think we're behind from a sort of effort or energy point of view right now.' As for whether he thinks a four-day week will be the norm in the future, Chandratillake was the bearer of bad news. 'Humans have a way of just making themselves more work. So I think the nature of the work will shift. I think the ways in which you can do it may be more flexible. 'But every 100 years or so, it seems like someone suggests that we're going to all work less, and unfortunately, they turn out to be wrong.' This story was originally featured on
Yahoo
44 minutes ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Yahoo
44 minutes ago
- Yahoo
Yumeiren International Group Shines at Malaysia's IBE
HANGZHOU, China, June 05, 2025--(BUSINESS WIRE)--The four-day 2025 Malaysia IBE (International Beauty Expo) concluded successfully in Kuala Lumpur. This year's event brought together over 400 international brands and attracted more than 16,000 professional buyers, forming a robust business network spanning 28 countries. As a leader in China's medical aesthetics going global, Yumeiren stood out at the expo with its integrated approach to life cosmetology, medical cosmetology, and greater health. The company invited Southeast Asian partners to join its service network—marking a strategic step in its global growth and advancing the international presence of China's medical cosmetology. From its founding in 1993 to its global debut in Kuala Lumpur, Yumeiren has spent 33 years shaping the sustained growth of a Chinese medical beauty brand. This is not merely business expansion—it is an industry evolution that has weathered economic cycles, embraced technological shifts, and bridged cultural divides. Under the leadership of President Yu Wenhong, Yumeiren built its foundation from the ground up, uniting lifestyle beauty and medical cosmetology into the Artistic Facial Shaping platform. With passion, vision, and professionalism, she guided the company into a new era of precision development—continuously enhancing service systems, integrating multidisciplinary health management, and expanding into the broader wellness space. Through strategic integration and innovation, Yumeiren launched its Forever Young Healthcare System, using science to slow aging and empowering individuals to take control of their health and longevity. Even before the expo began, numerous Malaysian organizations actively reached out to Yumeiren seeking collaboration. In response, President Yu Wenhong and her team arrived in Kuala Lumpur early to evaluate potential partners and begin training local doctors—ensuring seamless integration of Chinese aesthetic standards with Malaysian medical practices and establishing Yumeiren as part of the local ecosystem. During the expo, Yumeiren's booth drew large crowds. The team shared the company's growth story and brand strengths, deepening attendees' understanding and reinforcing confidence in the brand, while clearly communicating partnership expectations and value. With over 30 years of experience, Yumeiren has built a solid operational and brand framework that ensures reliability—earning lasting trust from clients and attracting an increasing number of committed partners. The success of this expo showcased Yumeiren's strengths and highlighted strong interest from global markets. Committed to delivering professional service, Yumeiren will continue bringing health, youth, and beauty to the world. View source version on Contacts Cathy Cai, ymrinternational@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
